Baxter International INC: management transactions · United States · SEC (Form 4)

About Baxter International INC

Baxter International Inc. (ticker BAX) is a U.S.-listed medical technology company traded on the NYSE in the United States. For French-, Belgian- and Swiss-based investors, Baxter is best understood as a defensive healthcare name with global exposure to hospitals, acute care settings and clinical infrastructure. Founded in 1931, the company is headquartered in Deerfield, Illinois, and has evolved from a long-established provider of infusion and hospital solutions into a broader medtech platform with meaningful positions in critical care and patient-care delivery. Baxter’s business is built around products and services used throughout the hospital workflow. Its portfolio includes infusion systems, parenteral nutrition, medication delivery, renal care therapies, emergency care devices, and a growing set of hospital infrastructure and connected-care solutions. Following the Hillrom acquisition, Baxter materially expanded its presence in smart beds, therapeutic surfaces, patient monitoring, and mobility solutions. That move broadened the company’s offering beyond consumables and core hospital supplies, creating a more integrated proposition for healthcare providers. From a competitive standpoint, Baxter holds a significant position among global suppliers of medical devices and hospital equipment. It competes with specialists across infusion therapy, monitoring, surgical and critical-care equipment, and clinical consumables. Its competitive advantages include a large installed base, recurring demand for consumables, deep customer relationships with hospitals, and the ability to bundle equipment, software and service components. This mix supports a business profile that is typically less cyclical than many industrial sectors, although margins and execution remain sensitive to manufacturing, pricing and regulatory discipline. Geographically, Baxter has a broad international footprint, with meaningful exposure to North America, Europe and other major healthcare markets. The company sells to hospitals, clinics and healthcare systems around the world, which supports scale but also introduces complexity in terms of regulation, supply chain management and product compliance. Recent developments point to a company in operational transition. In first-quarter 2026, Baxter said it was making progress toward stabilizing the business and reiterated its full-year outlook, while also noting added compliance costs related to European medical-device regulations. Earlier in 2026, Baxter introduced the Dynamo Series smart stretcher for emergency, perioperative and patient-transport use, and announced a strategic partnership with MUSC Health aimed at improving bedside care delivery and addressing nursing challenges. These initiatives reinforce Baxter’s focus on connected care, hospital workflow innovation and operational simplification. For investors, the key themes remain execution, portfolio optimization, regulatory compliance and the company’s ability to convert its broad installed base into steadier growth on the NYSE in the United States.